Hormone therapy and cardiovascular disease

Taiwanese Journal of Obstetrics and Gynecology

Volumn 45, Issue 4, 2006, Pages 287-293

  Chen, Fang Ping ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cardiovascular disease; Coronary artery disease; Estrogen; Hormone therapy

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING INHIBITOR; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FIBRINOGEN; FIBRINOLYTIC FACTOR; GESTAGEN; GESTODENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; TISSUE PLASMINOGEN ACTIVATOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; ESTROGEN DEFICIENCY; HEART INFARCTION; HORMONAL THERAPY; HUMAN; META ANALYSIS; NONHUMAN; POSTMENOPAUSE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; STROKE; SYSTEMATIC REVIEW;

EID: 33846265809     PISSN: 10284559     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1028-4559(09)60245-X     Document Type: Review

References (62)

1. Speroff L. Quality of life issues in the management of the menopause. In: Popkin D, Peddle L, eds. Women's Health Today. New York: Parthenon, 1994:271-90.
2. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328:1069-75.
3. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-56.
4. Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991: 164:489-94.
5. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
6. Folsom AR, Mink PJ, Sellers TA, Hong CP, Zheng W, Potter JD. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 1995;85:1128-32.
7. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Eng J Med 1996;335;453-61.
8. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75.
9. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133;933-41.
10. Ferrara A, Quesenberry CP, Karter AJ, Njoroge CW, Jacobson AS, Selby JV. Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanent Diabetes Registry, 1995-1998. Circulation 2003;107:43-8.
11. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
12. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen on postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
13. Writing Group for the Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Arch Itern Med 2006;166:357-65.
14. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-13.
15. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976;85:447-52.
16. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham study. Ann Intern Med 1978;89:157-61.
17. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993;98:83-90.
18. Armstrong VW, Cremer P, Eberle E. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis 1986;62:249-57.
19. Zenker G, Koeltringer P, Bone G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986;17:942-5.
20. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-4.
21. Schriewer H, Assman G, Sandkamp M. The relationship of Lp(a) to risk factors of coronary heart disease: initial results of the prospective epidemiological study on company employees in Westfalia. J Clin Chem Clin Biochem 1984;22:591-6.
22. Bruschi F, Meschia M, Soma MR et al. Lp(a) levels in perimenopausal years: a population study [abstract]. Symposium on Women's Health in Menopause, September 1993, Milan, Italy.
23. Scarabin PY. Haemostatic variables and arterial thrombotic disease: epidemiological evidence. In: Seghatchian MJ, Samama MM, Hecker SP, eds. Hypercoagulable States: Fundamental Aspects, Acquired Disorders, and Congenital Thrombophilis. Boca Raton, FL: CRC Press, 1996:209-16.
24. Meade TW, Haines AP, Imeson JD, Stirling Y, Thompson SG. Menopausal status and haemostatic variables. Lancet 1983; 1:22-4.
25. Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII: putative cardiovascular risk factors. Atherosclerosis 1991;91:191-205.
26. Meilahn EN, Kuller LH, Matthews KA, Kiss JE. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol 1992;2:445-55.
27. rd edition. Edinburgh: Churchill Livingstone, 1994:1349-60.
28. Meade TW, Cooper J, Miller GJ, Howarth D, Stirling Y. Antithrombin III and arterial disease. Lancet 1991;337:850-1.
29. Tait RC, Walker ID, Islam SIAM, McCall F, Conkie JA, Mitchell R, Davidson JE. Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol 1993a;84:476-80.
30. Conlan MG, Folsom AR, Finch A, Davis CE, Marcucci G, Sorlie P, Wu KK. Antithrombin III: associations with age, race, sex and cardiovascular disease risk factors. Thromb Haemost 1994;72:551-6.
31. Tait RC, Walker ID, Islam SIAM, et al. Protein C activity in healthy volunteers: influence of age, sex, smoking and oral contraceptives. Thromb Haemost 1993b;70:281-5.
32. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Wu KK. Correlation of plasma protein C levels with cardiovascular risk factors in middle-age adults: the ARIC Study. Thromb Haemost 1993b;70:762-7.
33. Lowe GDO, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, Tunstall-Pedoe H. Epidemiology of coagulation factors, inhibitors and activation markers: the third Glasgow MONICA survey I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997;97:775-84.
34. Thögersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Circulation 1998;98:2241-7.
35. Wiman B. Predictive value of fibrinolytic factors in coronary heart disease. Scand J Clin Lab Invest 1999;59:23-31.
36. Scarabin PY, Bonithon-Kopp C, Bara L, Guize L, Samama M. Relationship between plasminogen activator inhibitor activity and menopausal status. Fibrinolysis 1990;4:233-6.
37. Gebara OCE, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham offspring study. Circulation 1995;91:1952-8.
38. Sheuer J, Malthora A, Schaible TF, Capasso J. Effects of gonadectomy and hormonal replacement on rat hearts. Circ Res 1987;61:12-6.
39. Kangro T, Henriksen E, Jonason T, Leppert J, Nilsson H, Sörensen S, Ringqvist I. Effect of menopause on left ventricular filling in 50-year-old women. Am J Cardiol 1995;76: 1093-6.
40. Jonas HA, Kronmal RA, Psaty BM, et al. Current estrogen-progestin and estrogen replacement therapy in elderly women: association with carotid atherosclerosis. CHS Collaborative Research Group. Cardiovascular Health Study. Ann Epidemiol 1996;6:314-23.
41. Manolio TA, Furberg CD, Shemanski L, Psaty BM, O'Leary DH, Tracy RP, Bush TL. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. Circulation 1993;88:2163-71.
42. Herrington DM, Reboussin DM, Brodnihan KB, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000;343:522-9.
43. Angerer P, Stork S, Kothny W, Schmitt P, von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001;21:262-8.
44. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-53.
45. Byington RP, Gurberg CD, Herrington DM, et al. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. Arterioscler Thromb Vasc Biol 2002;22: 1692-7.
46. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-40.
47. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535-45.
48. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
49. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schodiel PM. A study of hormone replacement therapy in postmenopausal women with ischemic heart disease: the Papworth HRT atherosclerosis study. BJOG 2002;109:1056-62.
50. Cherry N, Gilmour K, Hnnaford P, et al; on behalf of the ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet 2002;360:2001-8.
51. Collins P, Flather M, Lees B, Mister R, Proudler AJ, Stevenson JC; WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. Eur Heart J 2006; 27:2046-53.
52. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.
53. Paganini-Hill A, Dworsky R, Krauss RM. Hormone replacement therapy, hormone levels, and lipoprotein cholesterol concentrations in elderly women. Am J Obstet Gynecol 1996; 174:897-902.
54. Chen FP, Lee N, Soong YK. Changes in the lipoprotein profile in postmenopausal women receiving hormone replacement therapy. J Reprod Med 1998;43:568-74.
55. Chen FP, Lee N, Wang CH, Cherng WJ, Soong YK. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril 1998;69:267-73.
56. Chen FP, Lee N, Soong YK, Huang KE. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors. Menopause 2001; 8:347-52.
57. Chen FP, Lee N, Soong YK, Huang KE. Short- and long-term effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Chang Gung Med J 2001;24:431-9.
58. Teng LF, Chen FP, Lee N. Changes in hemostasis and lipid metabolism in postmenopausal women receiving hormone replacement therapy: effects of natural and synthetic progestogens. Taiwanese J Obstet Gynecol 2004;43:80-7.
59. Gebara OCE, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995;91:1952-8.
60. Gilabert J, Estelles A, Cano A, et al. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol 1995;173:1849-54.
61. Shahar E, Folsom AR, Salomaa W, et al. Relation of hormone replacement therapy to measures of plasma fibrinolytic activity. Circulation 1996;93:1970-5.
62. Miller ME, Dores GM, Thorpe SL, Akerley WL. Paradoxical influence of estrogenic hormone on platelet-endothelial cell interactions. Thromb Res 1994;74:577-94.